Role of Rab25 in acquired resistance of non-small cell lung cancer against erlotinib in vitro

王旭东; 王江; 赵凤仪; 韩静; 孙建国; 陈正堂

您当前的位置：

首页 >

文章列表页 >

Role of Rab25 in acquired resistance of non-small cell lung cancer against erlotinib in vitro

更新时间：2026-01-09

- Role of Rab25 in acquired resistance of non-small cell lung cancer against erlotinib in vitro
- Journal of Army Medical University Vol. 38, Issue 7, Pages: 681-686(2016)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：
  CLC： R345;R734.2;R979.12
- Published：2016
- 稿件说明：
移动端阅览
王旭东,王江,赵凤仪,韩静,孙建国,陈正堂.Rab25在非小细胞肺癌厄洛替尼获得性耐药中的作用[J].陆军军医大学学报(原第三军医大学学报),2016,38(07):681-686.

　Wang Xudong,Wang Jiang,Zhao Fengyi,Han Jing,Sun Jianguo,Chen Zhengtang.Role of Rab25 in acquired resistance of non-small cell lung cancer against erlotinib in vitro[J].J Amry Med Univ (J Third Mil Med Univ),2016,38(07):681-686.
王旭东,王江,赵凤仪,韩静,孙建国,陈正堂.Rab25在非小细胞肺癌厄洛替尼获得性耐药中的作用[J].陆军军医大学学报(原第三军医大学学报),2016,38(07):681-686. DOI：

　Wang Xudong,Wang Jiang,Zhao Fengyi,Han Jing,Sun Jianguo,Chen Zhengtang.Role of Rab25 in acquired resistance of non-small cell lung cancer against erlotinib in vitro[J].J Amry Med Univ (J Third Mil Med Univ),2016,38(07):681-686. DOI：

摘要

目的探讨Rab25在非小细胞肺癌（non-small cell lung cancer，NSCLC）厄洛替尼获得性耐药中的作用。方法传代培养PC9及其厄洛替尼耐药PC9/ER细胞，采用CCK-8法检测PC9/ER细胞的耐药指数。应用实时荧光定量PCR（quantitative real-time，qPCR）及Western blot检测对比同等厄洛替尼浓度（0.1、0.2、0.3 μmol/L）处理条件下，Rab25在两种细胞中的mRNA及蛋白表达差异，并以免疫荧光法定位Rab25在细胞中的分布。用小干扰RNA（siRab25）转染PC9/ER细胞，并以流式细胞仪及CCK-8法分别检测Rab25敲减后PC9/ER细胞的增殖指数（proliferation index，PI）及厄洛替尼IC50值的变化。结果 PC9/ER细胞的耐药指数是68.82±21.42。相同厄洛替尼浓度处理48 h后，PC9/ER细胞Rab25 mRNA及蛋白水平均高于PC9细胞（P0.05），增高的Rab25蛋白主要表达于细胞膜。而且PC9/ER细胞Rab25蛋白水平随厄洛替尼处理浓度（0.1、0.2、0.3 μmol/L）递增而增高。siRab25在PC9/ER细胞中成功转染后，转染组的厄洛替尼IC

值及PI均明显低于对照组（P0.05）。结论 Rab25在NSCLC厄洛替尼获得性耐药细胞中高表达，起着促进耐药的作用。

Abstract

Objective To determine the role of Rab25 to erlotinib (ER) in acquired resistance of non-small cell lung cancer (NSCLC). Methods PC9 cells and the erlotinib acquired resistance cells (PC9/ER) were subcultured to evaluate erlotinib resistance index using CCK-8 assay. After treated with series concentrations of erlotinib (0.1

0.2 and 0.3 μmol/L)

the mRNA and protein levels of Rab25 were detected in the PC9 and PC9/ER cell

s by quantitative real-time PCR (qPCR) and Western blotting

respectively. Immunofluorescence assay was used to observe the subcellular localization of Rab25 in the cells. After knocking-down Rab25 in PC9/ER with siRab25

the changes of proliferation index (PI) and erlotinib IC

were detected by flow cytometry and CCK-8 assay respectively. Results The resistance index of PC9/ER to erlotinib was 68.82±21.42. The mRNA and protein levels of Rab25 were significantly higher in the PC9/ER cells than the PC9 cells after ER treatment for 48 h. In addition

the heaped Rab25 protein was mainly located in the cell membrane. Interestingly

the Rab25 protein level was progressively increased in a dose-dependent manner in PC9/ER cells

but not in PC9 cells. Erlotinib IC

and PI were much lower in the PC9/ER cells with Rab25 knockdown than the control cells (P＜0.05). Conclusion Rab25 is strongly expressed in acquired resistant NSCLC cells against ER

and it contributes to ER acquired resistance in the cells.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Role and mechanism of hexokinase 2 in erlotinib resistance in non-small cell lung cancer

Establishment of crizotinib-resistant non-small cell lung cancer cell line NCI-H3122 and preliminary study of resistance related miRNAs

Correlation of serum cytokine levels with erlotinib treatment outcome in patients with advanced non-small cell lung cancer

Integrative model combining deep learning, clinical and radiomic features enhances EGFR mutation prediction in non-small cell lung cancer

Preparation of doxorubicin-loaded polyphyllin H liposomes and synergistic anti-tumor activity against non-small cell lung cancer in vitro

Related Author

游启爱

卓文磊

陈正堂

刘晓

贾燕花

张可

刘皈阳

刘璐

Related Institution

Department of Radiology，First Affiliated Hospital， Army Medical University （Third Military Medical University）

Infervision Medical Technology Co.， Ltd

Department of Radiology， Daping Hospital， Army Medical University

Department of Diagnostic Radiology， Eastern Theatre General Hospital

Department of Medical Service,No. Hospital of Joint Logistics Support Force

⁰